Nuage Therapeutics raises €12M in Seed Financing led by Sofinnova Partners and Asabys - Capital-Riesgo.es
Summary
Nuage Therapeutics (Nuage), a biotech company developing a drug discovery engine for small molecule modulators of intrinsically disordered proteins (IDPs), announces today the successful closing of a 12 million Seed financing to support the development of its lead program and validate its pioneering drug discovery platform. The financing round was led by Sofinnova Partners, a leading European venture capital firm in life sciences, and Asabys, a venture capital firm based in Barcelona and specialized in the healthcare sector, with the participation of Innvierte, an investment program of CDTI Innovaci\xf3n, and BStartup.Nuage is a spin-off of IRB Barcelona and ICREA, founded by the researchers Xavier Salvatella, Mateusz Biesaga, Denes Hnisz, and Judit Anido, who is now the Chief Executive Officer (CEO) of Nuage. It aims to develop a strong pipeline in other untreatable cancer indications.Judit Anido, CEO of Nuage, comments IDPs, which perform fundamental cellular functions, are implicated in numerous human diseases. Based at the Barcelona Science Park, Nuage Therapeutics develops drug screening assays to target intrinsically disordered proteins that undergo biomolecular condensation, thus providing new treatments for diseases currently considered difficult to treat. Based in Paris, London and Milan, the firm brings together a team of professionals from all over the world with strong scientific, medical, and business expertise.